Market Summary
USD10.51-0.05
Delayed-0.47%
CGEM Alerts
CGEM Stock Price
CGEM RSI Chart
CGEM Valuation
CGEM Price/Sales (Trailing)
CGEM Profitability
CGEM Fundamentals
CGEM Revenue
CGEM Earnings
Price Action
52 Week Range
7.3015.89
(Low)(High)
Last 7 days
-3.2%
Last 30 days
-4.7%
Last 90 days
2.6%
Trailing 12 Months
-14.0%
CGEM Financial Health
CGEM Investor Care
Financials for Cullinan Oncology
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q4 | 2021Q3 |
| Revenue | -45.7% | 107 | 198 | 231 | 19.00 | 25.00 |
| Operating Expenses | -1.3% | 132 | 134 | 122 | 87.00 | - |
| S&GA Expenses | -5.1% | 40.00 | 42.00 | 38.00 | 29.00 | - |
| R&D Expenses | 0.5% | 92.00 | 92.00 | 85.00 | 58.00 | - |
| EBITDA | 3.6% | 151 | 146 | 253 | - | - |
| EBITDA Margin | 90.8% | 1.41* | 0.74* | 1.20* | - | - |
| Earnings Before Taxes | 3.6% | 151 | 146 | 155 | -67.48 | - |
| EBT Margin | 90.8% | 1.41* | 0.74* | 1.20* | - | - |
| Net Income | 7.1% | 111 | 104 | 111 | -65.57 | - |
| Net Income Margin | 97.2% | 1.04* | 0.52* | 0.33* | - | - |
| Free Cahsflow | -9.4% | -127 | -116 | -43.43 | - | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -9.1% | 561 | 617 | 667 | 437 | 437 |
| Current Assets | -18.5% | 474 | 582 | 623 | 322 | 297 |
| Cash Equivalents | -35.6% | 156 | 243 | 354 | 76.00 | 60.00 |
| Net PPE | 48.2% | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | -16.1% | 26.00 | 31.00 | 63.00 | 18.00 | 12.00 |
| Current Liabilities | -17.0% | 22.00 | 27.00 | 62.00 | 17.00 | 12.00 |
| Shareholder's Equity | -8.7% | 535 | 586 | 605 | 419 | 425 |
| Retained Earnings | -128.1% | -47.69 | -20.91 | 4.00 | -171 | -158 |
| Additional Paid-In Capital | -4.2% | 585 | 611 | 604 | 593 | 585 |
| Accumulated Depreciation | - | 0.00 | - | - | - | - |
| Shares Outstanding | 0.1% | 46.00 | 46.00 | 45.00 | 45.00 | 44.00 |
| Minority Interest | NaN% | - | - | 0.00 | 1.00 | 0.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -8.4% | -126 | -116 | -73.05 | -63.83 | -43.43 |
| Share Based Compensation | -14.2% | 28.00 | 33.00 | 32.00 | 27.00 | 24.00 |
| Cashflow From Investing | -4.9% | 249 | 262 | 294 | -161 | -333 |
| Cashflow From Financing | -367.9% | -25.93 | 10.00 | 9.00 | 8.00 | 269 |
Risks for CGEM
What is the probability of a big loss on CGEM?
88.8%
Probability that Cullinan Oncology stock will be more than 20% underwater in next one year
88.8%
Probability that Cullinan Oncology stock will be more than 30% underwater in next one year.
72.4%
Probability that Cullinan Oncology stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CGEM drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Cullinan Oncology was unfortunately bought at previous high price.
Drawdowns
Returns for CGEM
Cumulative Returns on CGEM
Which funds bought or sold CGEM recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | unchanged | - | -95,111 | 442,889 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -27,435 | 129,565 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | - | -14,000 | - | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | added | 5.62 | -44,490 | 297,510 | -% |
2023-02-15 | Tejara Capital Ltd | new | - | 248,980 | 248,980 | 0.14% |
2023-02-15 | Metropolitan Life Insurance Co/NY | added | 8.52 | -2,048 | 20,952 | -% |
2023-02-15 | MetLife Investment Management, LLC | reduced | -17.42 | -81,716 | 173,284 | -% |
2023-02-15 | Annandale Capital, LLC | unchanged | - | -22,000 | 106,000 | 0.04% |
2023-02-14 | Aquatic Capital Management LLC | new | - | 75,000 | 75,000 | -% |
2023-02-14 | SVB FINANCIAL GROUP | new | - | 285,188 | 285,188 | 0.78% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
CGEM Alerts
Cullinan Oncology News
Schedule 13G FIlings of Cullinan Oncology
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 15, 2023 | jovan-embiricos morana | 3.4% | 1,577,440 | SC 13G/A | |
| Feb 14, 2023 | biotechnology value fund l p | 8.9% | 4,058,854 | SC 13G/A | |
| Feb 13, 2023 | chi advisors llc | 7.25% | 3,317,544 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 6.15% | 2,812,965 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 5.5% | 2,506,215 | SC 13G | |
| Feb 14, 2022 | biotechnology value fund l p | 6.4% | 2,790,018 | SC 13G/A | |
| Feb 11, 2022 | foresite capital fund v, l.p. | 2.6% | 1,143,006 | SC 13G/A | |
| Feb 11, 2022 | chi advisors llc | 5.67% | 2,476,720 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 5.42% | 2,366,808 | SC 13G |
CGEM Fair Value
Recent SEC filings of Cullinan Oncology
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 09, 2023 | 10-K | Annual Report | |
| Mar 09, 2023 | 8-K | Current Report | |
| Mar 09, 2023 | S-3 | S-3 | |
| Mar 09, 2023 | S-8 | Employee Benefits Plan | |
| Mar 09, 2023 | S-8 | Employee Benefits Plan | |
| Feb 23, 2023 | 4 | Insider Trading | |
| Feb 21, 2023 | 4 | Insider Trading | |
| Feb 21, 2023 | 4 | Insider Trading | |
| Feb 21, 2023 | 4 | Insider Trading | |
| Feb 21, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for CGEM
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-02-22 | AHMED NADIM | acquired | - | - | 109,000 | president and ceo |
2023-02-17 | Michaelson Jennifer | acquired | - | - | 38,500 | chief development officer |
2023-02-17 | Trigilio Jeffrey | acquired | - | - | 47,000 | chief financial officer |
2023-02-17 | Jones Jeffrey Alan | acquired | - | - | 60,000 | chief medical officer |
2023-02-17 | SUMER JACQUELYN L | acquired | - | - | 47,000 | chief legal officer |
2023-02-17 | Baeuerle Patrick | acquired | - | - | 38,500 | chief scientific officer |
2023-02-17 | Savill Corrine | acquired | - | - | 20,500 | chief business officer |
2023-01-19 | BVF PARTNERS L P/IL | sold | - | - | -6,400,000 | - |
2022-12-30 | Trigilio Jeffrey | acquired | 1,802 | 8.97 | 201 | chief financial officer |
2022-11-25 | Michaelson Jennifer | sold | -53,200 | 13.3 | -4,000 | see remarks |
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
CGEM Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | |
| Income Statement [Abstract] | ||
| Revenue | $ 0 | $ 18,943 |
| Type of revenue [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember |
| Operating expenses: | ||
| Research and development | $ 91,948 | $ 57,751 |
| General and administrative | 40,189 | 29,146 |
| Total operating expenses | 132,137 | 86,897 |
| Gain on sale of Cullinan Pearl | 276,785 | 0 |
| Income (loss) from operations | 144,648 | (67,954) |
| Other income (expense): | ||
| Interest income | 6,611 | 477 |
| Other income (expense), net | 57 | (8) |
| Net income (loss) before income taxes | 151,316 | (67,485) |
| Income tax expense | 42,121 | 0 |
| Net income (loss) | 109,195 | (67,485) |
| Net loss attributable to noncontrolling interest | (2,019) | (1,915) |
| Net income (loss) attributable to common stockholders of Cullinan | 111,214 | (65,570) |
| Comprehensive income (loss): | ||
| Net income (loss) | 109,195 | (67,485) |
| Unrealized loss on investments | (1,763) | (836) |
| Comprehensive income (loss) | 107,432 | (68,321) |
| Comprehensive loss attributable to noncontrolling interest | (2,019) | (1,915) |
| Comprehensive income (loss) attributable to Cullinan | $ 109,451 | $ (66,406) |
| Earnings (net loss) per share: | ||
| Earnings Per Share, Basic | $ 2.46 | $ (1.52) |
| Earnings Per Share, Diluted | $ 2.38 | $ (1.52) |
| Weighted-average shares used in computing earnings (net loss) per share: | ||
| Weighted Average Number of Shares Outstanding, Basic | 45,164 | 43,077 |
| Weighted Average Number of Shares Outstanding, Diluted | 46,640 | 43,077 |
CGEM Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 156,152 | $ 59,774 |
| Short-term investments | 311,140 | 230,692 |
| Prepaid expenses and other current assets | 7,180 | 6,098 |
| Total current assets | 474,472 | 296,564 |
| Property and equipment, net | 1,174 | 77 |
| Operating lease right-of-use assets | 4,130 | 0 |
| Other assets | 459 | 147 |
| Long-term investments | 80,882 | 140,397 |
| Total assets | 561,117 | 437,185 |
| Current liabilities: | ||
| Accounts payable | 2,660 | 3,169 |
| Accrued expenses and other current liabilities | 14,135 | 8,577 |
| Income tax payable | 4,282 | |
| Operating lease liabilities, current | 1,421 | |
| Total current liabilities | 22,498 | 11,746 |
| Long-term liabilities: | ||
| Lease liabilities, non-current | 3,590 | |
| Deferred rent | 0 | 65 |
| Total liabilities | 26,088 | 11,811 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2022 and 2021; no shares issued and outstanding as of December 31, 2022 and 2021, respectively. | ||
| Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2022 and 2021; 45,796,449 and 44,292,102 shares issued and outstanding as of December 31, 2022 and 2021, respectively. | 5 | 4 |
| Additional paid-in capital | 585,320 | 584,714 |
| Accumulated other comprehensive loss | (2,601) | (838) |
| Accumulated deficit | (47,695) | (158,909) |
| Total Cullinan stockholders' equity | 535,029 | 424,971 |
| Noncontrolling interests | 0 | 403 |
| Total stockholders' equity | 535,029 | 425,374 |
| Total liabilities and stockholders' equity | $ 561,117 | $ 437,185 |